Stock Price Movement and Market Context
On 24 Nov 2025, Epigral's share price touched an intraday low of Rs.1428, representing a fall of 2.08% during the trading session. This decline contributed to a day change of -1.87%, underperforming its sector by 0.85%. The stock is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained downward momentum.
In contrast, the broader market has shown resilience. The Sensex opened 88.12 points higher and was trading at 85,343.57, up 0.13% on the day. The index remains close to its 52-week high of 85,801.70, just 0.54% away, supported by mega-cap stocks leading the gains. The Sensex has also recorded a 2.56% rise over the past three weeks, trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a bullish trend for the benchmark index.
Long-Term and Recent Performance Analysis
Epigral's one-year performance shows a decline of 26.32%, contrasting with the Sensex's positive return of 7.85% over the same period. The stock's 52-week high was Rs.2195.85, highlighting the extent of the recent price erosion. Over the last three years, the stock has also underperformed the BSE500 index across multiple time frames, including the last three months and one year.
Financially, the company has experienced subdued growth in operating profit, with an annual rate of -5.49% over the past five years. The latest quarterly results for September 2025 reveal a mixed picture: interest expenses for the last six months stood at Rs.45.21 crores, reflecting a growth of 286.41%, while the profit after tax (PAT) for the quarter was Rs.51.22 crores, showing a decline of 52.6% compared to the previous four-quarter average. Additionally, the operating profit to net sales ratio for the quarter was recorded at 22.53%, the lowest in recent periods.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Financial Strength and Valuation Metrics
Despite the recent price weakness, Epigral demonstrates strong management efficiency, with a return on capital employed (ROCE) of 23.19%. The company maintains a low debt burden relative to earnings, with a Debt to EBITDA ratio of 1.34 times, indicating a solid capacity to service its debt obligations.
Valuation metrics show a ROCE of 19.3% alongside an enterprise value to capital employed ratio of 2.6, suggesting a fair valuation framework. The stock is trading at a discount compared to the average historical valuations of its peers within the Specialty Chemicals sector. Over the past year, while the stock price has declined by 26.32%, the company's profits have risen by 37.1%, resulting in a price/earnings to growth (PEG) ratio of 0.5.
Shareholding and Market Position
The majority shareholding in Epigral is held by promoters, reflecting concentrated ownership. The company operates within the Specialty Chemicals industry, a sector that has seen varied performance across its constituents in recent months.
Holding Epigral from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns
The stock's decline to Rs.1428 marks a significant technical level, reflecting ongoing pressures from both recent quarterly results and longer-term growth trends. The substantial rise in interest expenses over the last six months and the sharp fall in quarterly PAT have contributed to the subdued market sentiment. Furthermore, the operating profit margin to net sales ratio at its lowest quarterly level adds to the cautious outlook on near-term financial performance.
Trading below all major moving averages indicates that the stock is currently in a downtrend, which contrasts with the broader market's positive trajectory. This divergence highlights sector-specific or company-specific factors influencing Epigral's share price movement.
Market and Sector Comparison
While the Sensex has been on a three-week consecutive rise, supported by mega-cap stocks and bullish moving averages, Epigral's performance has lagged behind both the benchmark and its sector peers. The stock's underperformance relative to the BSE500 index over multiple time frames underscores the challenges faced by the company in maintaining competitive momentum.
Investors and market participants may note the contrast between the company's strong management efficiency and debt servicing ability against the backdrop of recent financial results and stock price performance.
Conclusion
Epigral's fall to a 52-week low of Rs.1428 reflects a combination of recent quarterly financial outcomes, longer-term growth patterns, and technical price movements. The stock's current valuation metrics and financial ratios provide a nuanced picture, balancing operational efficiency and debt management against recent earnings pressures and market underperformance. As the broader market continues to show strength, Epigral's position within the Specialty Chemicals sector remains under close observation.
Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →
